Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

27 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB. Loeb S, et al. Among authors: antenor ja. Urology. 2006 Feb;67(2):316-20. doi: 10.1016/j.urology.2005.08.040. Epub 2006 Jan 25. Urology. 2006. PMID: 16442597
Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S, Nadler RB, Roehl KA, Antenor JA, Catalona WJ. Loeb S, et al. Among authors: antenor ja. J Urol. 2007 May;177(5):1745-8. doi: 10.1016/j.juro.2007.01.068. J Urol. 2007. PMID: 17437803
Prostate specific antigen density correlates with features of prostate cancer aggressiveness.
Kundu SD, Roehl KA, Yu X, Antenor JA, Suarez BK, Catalona WJ. Kundu SD, et al. Among authors: antenor ja. J Urol. 2007 Feb;177(2):505-9. doi: 10.1016/j.juro.2006.09.039. J Urol. 2007. PMID: 17222621
Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ. Roehl KA, et al. Among authors: antenor ja. Urol Oncol. 2006 Nov-Dec;24(6):465-71. doi: 10.1016/j.urolonc.2005.11.039. Urol Oncol. 2006. PMID: 17138126
Characteristics of patients with familial versus sporadic prostate cancer.
Roehl KA, Loeb S, Antenor JA, Corbin N, Catalona WJ. Roehl KA, et al. Among authors: antenor ja. J Urol. 2006 Dec;176(6 Pt 1):2438-42; discussion 2442. doi: 10.1016/j.juro.2006.07.159. J Urol. 2006. PMID: 17085123
Lymphovascular invasion in radical prostatectomy specimens: prediction of adverse pathologic features and biochemical progression.
Loeb S, Roehl KA, Yu X, Antenor JA, Han M, Gashti SN, Yang XJ, Catalona WJ. Loeb S, et al. Among authors: antenor ja. Urology. 2006 Jul;68(1):99-103. doi: 10.1016/j.urology.2006.02.004. Epub 2006 Jun 27. Urology. 2006. PMID: 16806410
Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.
Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL, Catalona WJ. Loeb S, et al. Among authors: antenor ja. J Urol. 2006 Mar;175(3 Pt 1):902-6. doi: 10.1016/S0022-5347(05)00327-7. J Urol. 2006. PMID: 16469576
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
Nadler RB, Loeb S, Roehl KA, Antenor JA, Eggener S, Catalona WJ. Nadler RB, et al. Among authors: antenor ja. J Urol. 2005 Dec;174(6):2154-7, discussion 2157. doi: 10.1097/01.ju.0000181213.07447.8f. J Urol. 2005. PMID: 16280754
Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
Zhu H, Roehl KA, Antenor JA, Catalona WJ. Zhu H, et al. Among authors: antenor ja. Urology. 2005 Sep;66(3):547-51. doi: 10.1016/j.urology.2005.03.093. Urology. 2005. PMID: 16140075
Results of compliance with prostate cancer screening guidelines.
Grubb RL, Roehl KA, Antenor JA, Catalona WJ. Grubb RL, et al. Among authors: antenor ja. J Urol. 2005 Aug;174(2):668-72; discussion 672. doi: 10.1097/01.ju.0000165149.66186.23. J Urol. 2005. PMID: 16006944
27 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback